Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999544 · ClinicalTrials.gov registry record · NA
Aprepitant Effects on Oxycodone Response
A NA study, sponsored by Sharon Walsh.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT00999544 is a NA study that has completed, run by Sharon Walsh. The registered enrollment target is 9 participants.
The verdict
NCT00999544, a NA study, has completed, sponsored by Sharon Walsh.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.
Interventions
- DRUG Aprepitant 0mg
- DRUG Aprepitant 40mg
- DRUG Aprepitant 200mg
- DRUG Oxycodone 0mg, p.o.
- DRUG Oxycodone 20mg, p.o.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00999544
The ClinicalTrials.gov registry entry for NCT00999544 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sharon Walsh, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aprepitant 0mg is the first listed.
NCT00999544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00999544 about?
NCT00999544 is a clinical study titled "Aprepitant Effects on Oxycodone Response". Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute...
What is the current status of trial NCT00999544?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2009-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00999544?
The interventions under investigation include: Aprepitant 0mg (DRUG), Aprepitant 40mg (DRUG), Aprepitant 200mg (DRUG), Oxycodone 0mg, p.o. (DRUG), Oxycodone 20mg, p.o. (DRUG).
Who is sponsoring clinical trial NCT00999544?
This trial is sponsored by Sharon Walsh, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.